Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 13/20 | 0.48 |
| ▸ | RAB9A | P51151 | 11/20 | 0.48 |
| ▸ | NPC1 | O15118 | 9/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2225131 | 0.90 | KMT2A (0.45) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL2223866 | 0.85 | PTPN1 (0.42) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL2223131 | 0.85 | MAPT (0.45) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL2225569 | 0.85 | SMN1; SMN2 (0.54) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL12805900 | 0.84 | PTPN1 (0.42) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL12937598 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL2225352 | 0.82 | PTPN1 (0.40) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL12516993 | 0.81 | RAB9A (0.40) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL2225223 | 0.81 | SMN1; SMN2 (0.52) | SMN1; SMN2RAB9ANPC1MEN1KMT2A | |
| SCHEMBL2226835 | 0.81 | PTPN1 (0.41) | SMN1; SMN2RAB9ANPC1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8907098-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-8907098-B2 | Inhibitors of sphingosine kinase | MERCK PATENT GMBH (DE) | 2014-12-09 | — | — | US | disclosed |
| US-20120252815-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252815-A1 | INHIBITORS OF SPHINGOSINE KINASE | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-10-04 | — | — | US | disclosed |
| WO-2011082732-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011082732-A1 | SPHINGOSINE KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2011-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252815-A1 | INHIBITORS OF SPHINGOSINE KINASE | SPHK1, S1PR3, SPHK2 | SMN1; SMN2 613/4885RAB9A 1129/4885NPC1 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.